^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IMA950
i
Other names: IMA950
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Cancer Research UK, Immatics, University Hospitals of Geneva
Drug class:
Immunostimulant
Related drugs:
5ms
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) (clinicaltrials.gov)
P1, N=14, Terminated, Nicholas Butowski | Active, not recruiting --> Terminated; Industry sponsor decision
Trial termination
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
varlilumab (CDX 1127) • Hiltonol (poly-ICLC) • IMA950
1year
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. (PubMed, Neuro Oncol)
The combinational immunotherapy, including varlilumab, was well-tolerated and induced vaccine-reactive T-cell expansion in the peripheral blood but without a detectable response in the tumor. Further developments of strategies to overcome the blood-tumor barrier are warranted to improve the efficacy of immunotherapy for LGG patients.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD27 (CD27 Molecule)
|
varlilumab (CDX 1127) • Hiltonol (poly-ICLC) • IMA950
over1year
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Nicholas Butowski | Trial completion date: Dec 2022 --> Dec 2030
Trial completion date
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
HLA-A2 positive
|
varlilumab (CDX 1127) • Hiltonol (poly-ICLC) • IMA950
almost2years
IMA950-106: Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma (clinicaltrials.gov)
P1/2, N=18, Active, not recruiting, University Hospital, Geneva | Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2021 --> Dec 2023
Enrollment closed • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
HLA-A*02:01
|
Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • IMA950
over3years
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Nicholas Butowski | Recruiting --> Active, not recruiting | N=30 --> 14
Clinical • Enrollment closed • Enrollment change
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
HLA-A2 positive • HLA-A*02 positive
|
varlilumab (CDX 1127) • Hiltonol (poly-ICLC) • IMA950
over3years
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) (clinicaltrials.gov)
P1, N=30, Recruiting, Nicholas Butowski | Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Dec 2022
Clinical • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
varlilumab (CDX 1127) • Hiltonol (poly-ICLC) • IMA950
Share via
